Zai Lab (ZLAB) Total Non-Current Liabilities (2022 - 2026)
Zai Lab (ZLAB) reported Total Non-Current Liabilities of $433.7 million for Q1 2026, up 19.73% on a YoY basis from $362.3 million in Q1 2025, and down 5.07% sequentially from $456.9 million in Q4 2025.
Zai Lab (ZLAB) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Zai Lab (ZLAB) has 5 years of Total Non-Current Liabilities data on file, last reported at $433.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 19.73% year-over-year to $433.7 million; the trailing twelve-month figure through Mar 2026 stood at $433.7 million (up 19.73% YoY), and the FY2025 full-year result was $456.9 million, up 32.61% from the prior year.
- Total Non-Current Liabilities retreated to $433.7 million in Q1 2026, from $456.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $456.9 million in Q4 2025 to a low of $162.4 million in Q3 2023.
- A 5-year average of $293.8 million and a median of $300.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities surged 95.43% in 2024 and rose 19.73% in 2026, its largest moves.
- Tracing ZLAB's Total Non-Current Liabilities over 5 years: stood at $174.5 million in 2022, then soared by 37.42% to $239.9 million in 2023, then surged by 43.64% to $344.5 million in 2024, then soared by 32.61% to $456.9 million in 2025, then slipped by 5.07% to $433.7 million in 2026.
- Business Quant data shows ZLAB's Total Non-Current Liabilities at $433.7 million in Q1 2026, $456.9 million in Q4 2025, and $398.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Zai Lab | 21.37 Bn | 21.37 Bn | -34.26 Mn | 433.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 433.72 Mn |
| Dec 31, 2025 | 456.88 Mn |
| Sep 30, 2025 | 398.67 Mn |
| Jun 30, 2025 | 372.04 Mn |
| Mar 31, 2025 | 362.25 Mn |
| Dec 31, 2024 | 344.53 Mn |
| Sep 30, 2024 | 317.35 Mn |
| Jun 30, 2024 | 282.86 Mn |
| Mar 31, 2024 | 225.94 Mn |
| Dec 31, 2023 | 239.85 Mn |
| Sep 30, 2023 | 162.39 Mn |
| Jun 30, 2023 | 173.73 Mn |
| Mar 31, 2023 | 168.51 Mn |
| Dec 31, 2022 | 174.55 Mn |